文章：

非小细胞肺癌中长链非编码RNA介导的耐药机制

Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer 

原文发布日期：2020-08-25 

英文摘要：

Non-small-cell lung cancer (NSCLC) is the most prevalent form of lung cancer and has a poor five-year survival rate of 15%. Chemotherapy and targeted therapies have significantly improved patients’ prognosis. Nevertheless, after a successful initial response, some patients relapse when cancer cells become resistant to drug treatments, representing an important clinical limitation. Therefore, investigating the mechanisms of drug resistance is of significant importance. Recently, considerable attention has been given to long non-coding RNAs (lncRNAs), a heterogeneous class of regulatory molecules that play essential roles in tumorigenesis by modulating genes and signalling pathways involved in cell growth, metastasis and drug response. In this article, we review recent research findings on the role of lncRNAs in drug resistance in NSCLC, highlighting their mechanisms of action. 

摘要翻译： 

非小细胞肺癌（NSCLC）是最常见的肺癌类型，其五年生存率仅为15%，预后较差。化学疗法和靶向治疗显著改善了患者的预后状况。然而部分患者在获得初期疗效后，由于癌细胞产生耐药性而导致疾病复发，这已成为重要的临床治疗瓶颈。因此探究耐药机制具有重大意义。近年来，长链非编码RNA（lncRNA）作为一类异质性调控分子受到广泛关注，它们通过调控细胞生长、转移和药物反应相关基因及信号通路，在肿瘤发生发展中起关键作用。本文综述了lncRNAs在NSCLC耐药性中的作用机制及相关最新研究发现。

原文链接：

Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer